💊FDA PHARMA today
FDA approves Admelog, the first short-acting “follow-on” insulin product to treat diabetes FDA approves Admelog, the first short-acting “follow-on” insulin product to treat diabetes
The FDA today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus.
Admelog is the first short-acting insulin approved as a “follow-on” product.
Admelog received tentative approval from the FDA on Sept. 1, 2017 and is now being granted final approval.
The approval of Admelog was granted to Sanofi-Aventis U.S.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm588466.htm